1.上海中医药大学附属曙光医院眼科(上海 201203)
杨宇琴,女,硕士研究生,住院医师,主要从事中西医结合治疗眼底病临床及基础研究工作
邹红,副主任医师,硕士研究生导师; E-mail:zouhong2007@126.com
扫 描 看 全 文
杨宇琴,唐慧新,李景景,等.加味桃红四物汤阻断大鼠视网膜静脉阻塞模型JAK2⁃STAT3通路活化的机制[J].上海中医药杂志,2022,56(10):71-75.
YANG Yuqin,TANG Huixin,LI Jingjing,et al.Mechanism of Modified Taohong Siwu Decoction blocking JAK2⁃STAT3 pathway activation in rat model of retinal vein occlusion[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(10):71-75.
杨宇琴,唐慧新,李景景,等.加味桃红四物汤阻断大鼠视网膜静脉阻塞模型JAK2⁃STAT3通路活化的机制[J].上海中医药杂志,2022,56(10):71-75. DOI: 10.16305/j.1007-1334.2022.2202013.
YANG Yuqin,TANG Huixin,LI Jingjing,et al.Mechanism of Modified Taohong Siwu Decoction blocking JAK2⁃STAT3 pathway activation in rat model of retinal vein occlusion[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(10):71-75. DOI: 10.16305/j.1007-1334.2022.2202013.
目的,2,观察加味桃红四物汤对视网膜静脉阻塞(RVO)大鼠模型Janus激酶蛋白2-信号转导及转录因子3(JAK2-STAT3)通路的影响。,方法,2,将8周龄90只SD大鼠随机分成空白组(A组)、模型组(B组)、加味桃红四物汤高浓度组(C组)、加味桃红四物汤中浓度组(D组)、加味桃红四物汤低浓度组(E组),每组18只。A组不做处理,其他组大鼠右眼使用激光联合孟加拉玫瑰红的方法建立SD大鼠RVO模型。造模成功后,A组与B组予2 mL无菌注射液灌胃,C组、D组、E组灌胃给予低浓度(10 mg/kg)、中浓度(20 mg/kg)、高浓度(40 mg/kg)的加味桃红四物汤。给药后7、14、21 d用HE染色观察各组大鼠的视网膜结构、厚度和节细胞层(GCL)水肿情况,采用Western blot法检测21 d时视网膜组织中Janus激酶蛋白2(JAK2)、磷酸化Janus激酶蛋白2(P-JAK2)、信号转导及转录因子3(STAT3)、磷酸化信号转导及转录因子3(P-STAT3)的蛋白表达。,结果,2,①视网膜结构:7 d时各组视网膜3层结构完整,14 d时各组见散在视网膜静脉血管内血栓部分再通,21 d时各组节细胞数量改变不明显。视网膜厚度:7 d时B组、C组、E组见视网膜神经纤维层的间隙增宽;14 d及21 d时C、D、E组视网膜厚度均变薄。GCL水肿:7 d时各组GCL水肿,14 d时C组、D组、E组GCL水肿减轻,21 d时各组GCL无水肿。②JAK2蛋白表达:与A组比较,B组JAK2蛋白表达降低(,P<,0.05);与B组比较,C组、D组JAK2蛋白表达升高(,P<,0.05);与E组比较,C组、D组JAK2蛋白表达较高(,P<,0.05)。P-JAK2蛋白表达:与A组比较,B组、E组P-JAK2蛋白表达升高(,P<,0.05);与B组比较,C组、D组、E组P-JAK2蛋白表达降低(,P<,0.05);与E组比较,C组、D组P-JAK2蛋白表达较低(,P<,0.05)。STAT3蛋白表达:与A组比较,D组STAT3蛋白表达降低,E组STAT3蛋白表达升高(,P<,0.05);与B组比较,C组STAT3蛋白表达降低,E组STAT3蛋白表达升高(,P<,0.05);与E组比较,C组、D组STAT3蛋白表达较低(,P<,0.05)。P-STAT3蛋白表达:与A组比较,B组、C组P-STAT3蛋白表达升高(,P<,0.05);与B组比较,C组P-STAT3蛋白表达降低(,P<,0.05)。,结论,2,加味桃红四物汤可改善眼底缺血缺氧,阻断RVO的发展,其机制可能与抑制JAK2-STAT3通路活化相关。
Objective,2,To observe the effect of Modified Taohong Siwu Decoction (MTHSWD) on JAK2-STAT3 pathways in rat model of retinal vein occlusion (RVO).,Methods,2,Ninety SD rats aged 8 weeks were randomly divided into blank control group (group A), model control group (group B), MTHSWD high concentration group (group C), MTHSWD medium concentration group (group D), MTHSWD low concentration group (Group E) with 18 rats in each group. Group A was left untreated, and the right eyes of rats in other groups were treated with laser combined with Rose Bengal to establish the RVO model in SD rats. After successful modeling, groups A and B were given 2 mL of sterile injection by gavage, and groups C, D and E were given low (10 mg/kg), medium (20 mg/kg) and high (40 mg/kg) concentrations of MTHSWD by gavage. The retinal structure, thickness and edema of ganglion cell layer (GCL) were observed by HE staining at 7, 14 and 21 days after administration. The protein expressions of Janus kinase protein 2 (JAK2), Janus kinase protein 2 phosphorylation (P-JAK2), signal transduction and transcription factor 3 (STAT3), signal transduction and transcription factor 3 phosphorylation (P-STAT3) in retina were detected by Western blot method.,Results,2,①Retinal structure: The structure of three layers of retina in each group was intact on the 7th day, and partial recanalization of thrombus in the retinal vein was found in each group on the 14th day, and there was no significant change in the number of ganglion cells in each group on the 21st day. Retinal thickness: The gap of retinal nerve fiber layer was broadened in group B, C and E on the 7th day, and the retinal thickness became thinner in group C, D and E on the 14th and 21st day. GCL edema: GCL edema in each group on the 7th day and the edema in C, D and E groups on the 14th day alleviated, and GCL had no edema on the 21st day. ②Expression of JAK2 protein: Compared with group A, the expression of JAK2 protein in group B was lower (,P<,0.05), the expression of JAK2 protein in group C and D was higher than that in group B (,P<,0.05), and the expression of JAK2 protein in group C and D was higher than that in group E (,P<,0.05). The expression of P-JAK2 protein: Compared with group A, the expression of P-JAK2 in group B and E was higher (,P<,0.05), the expression of P-JAK2 in group C, D and E was lower than that in group B (,P,<,0.05), and the expression of P-JAK2 in group C and D was lower than that in group E (,P<,0.05). The expression of STAT3 protein: Compared with group A, the expression of STAT3 protein in group D decreased, and the expression of STAT3 protein increased in group E (,P<,0.05). Compared with group B, the expression of STAT3 protein decreased in group C and increased in group E (,P<,0.05). Compared with group E, the expression of STAT3 protein in group C and D was lower (,P<,0.05). The expression of P-STAT3 protein: Compared with group A, the expression of P-STAT3 protein in group B and C was higher (,P<,0.05), and the expression of P-STAT3 protein in group C was lower than that in group B (,P<,0.05).,Conclusion,2,Modified Taohong Siwu Decoction can improve fundus ischemia and hypoxia and block the development of RVO, and its mechanism may be related to the inhibition of JAK2-STAT3 pathway activation.
视网膜静脉阻塞加味桃红四物汤Janus激酶蛋白2信号转导及转录因子3大鼠模型中药研究
retinal vein occlusionModified Taohong Siwu DecoctionJAK2STAT3rat modeltraditional Chinese herbal medicine research
SONG P, XU Y, ZHA M, et al. Global epidemiology of retinal vein occlusion: a systematic review and meta-analysis of prevalence, incidence, and risk factors[J]. J Glob Health, 2019, 9(1): 010427.
KHAYAT M, LOIS N, WILLIAMS M, et al. Animal models of retinal vein occlusion[J]. Invest Ophthalmol Vis Sci, 2017, 58(14): 6175-6192.
LANG G E, LANG S J. Retinal vein occlusions[J]. Klin Monbl Augenheilkd, 2018, 235(11): 1297-1315.
BREMOND-GIGNAC D. Investigational drugs for retinal vein occlusion[J]. Expert Opin Investig Drugs, 2016, 25(7): 841-850.
BOYLE D L, SOMA K, HODGE J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis[J]. Ann Rheum Dis, 2015, 74(6): 1311-1316.
REILLEY M J, MCCOON P, COOK C, et al. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial[J]. J Immunother Cancer, 2018, 6(1): 119.
LI X, CAI Y, WANG Y S, et al. Hyperglycaemia exacerbates choroidal neovascularisation in mice via the oxidative stress-induced activation of STAT3 signalling in RPE cells[J]. PLoS One, 2012, 7(10): e47600.
CHEN W, WU Y, ZHENG M, et al. Establishing an experimental rat model of photodynamically-induced retinal vein occlusion using erythrosin B[J]. Int J Ophthalmol, 2014, 7(2): 232-238.
GAO Y, ZHAO H L, WANG P, et al. The roles of SOCS3 and STAT3 in bacterial infection and inflammatory diseases[J]. Scand J Immunol, 2018, 88(6): e12727.
KIU H, NICHOLSON S E. Biology and significance of the JAK/STAT signalling pathways[J]. Growth Factors, 2012, 30(2): 88-106.
SERRA LÓPEZ-MATENCIO J M, MORELL BALADRÓN A, CASTAÑEDA S. JAK-STAT inhibitors for the treatment of immunomediated diseases[J]. Med Clin (Barc), 2019, 152(9): 353-360.
郝晓凤,谢立科. 视网膜静脉阻塞疾病中关于“积”的理论探讨[J]. 中国中医眼科杂志,2018, 28(4): 255-258.
张铭连,张越,王浩,等. 中医整体观念对缺血性眼病的认识[J]. 中国中医眼科杂志,2015, 25(6): 408-411.
赵连政,王小平. 基于顺势思维探讨《黄帝内经》中痈疽的治疗[J]. 山东中医药大学学报,2021, 45(3): 317-321.
0
浏览量
199
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构